As of 2026-09-16, the Intrinsic Value of Rigel Pharmaceuticals Inc (RIGL) is 74.94 USD. This RIGL valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 44.48 USD, the upside of Rigel Pharmaceuticals Inc is 68.50%.
The range of the Intrinsic Value is 61.83 - 96.19 USD
Based on its market price of 44.48 USD and our intrinsic valuation, Rigel Pharmaceuticals Inc (RIGL) is undervalued by 68.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 61.83 - 96.19 | 74.94 | 68.5% |
| DCF (Growth 10y) | 72.98 - 112.83 | 88.26 | 98.4% |
| DCF (EBITDA 5y) | 86.68 - 112.07 | 103.53 | 132.7% |
| DCF (EBITDA 10y) | 92.42 - 127.29 | 112.29 | 152.4% |
| Fair Value | 435.01 - 435.01 | 435.01 | 878.00% |
| P/E | 107.88 - 388.38 | 250.20 | 462.5% |
| EV/EBITDA | 67.38 - 120.43 | 97.11 | 118.3% |
| EPV | 21.11 - 29.30 | 25.20 | -43.3% |
| DDM - Stable | 113.70 - 228.81 | 171.26 | 285.0% |
| DDM - Multi | 43.47 - 70.64 | 54.03 | 21.5% |
| Market Cap (mil) | 822.88 |
| Beta | 1.12 |
| Outstanding shares (mil) | 18.50 |
| Enterprise Value (mil) | 801.30 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.28% |
| Cost of Debt | 8.56% |
| WACC | 9.22% |